Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (81-90 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|March 8, 2022
Maintenance capecitabine is beneficial in NPCDavid Killock
Nature Reviews. Clinical Oncology|May 9, 2019
GITR agonism - combination is keyDavid Killock
Nature Reviews. Clinical Oncology|July 28, 2023
Adjuvant nivolumab shows promise in MCCDavid Killock
Nature Reviews. Clinical Oncology|July 21, 2023
Platinum-ineligible: atezolizumab preferableDavid Killock
Nature Reviews. Clinical Oncology|June 24, 2024
Vimseltinib improves outcomes in tenosynovial giant cell tumourDavid Killock
Nature Reviews. Clinical Oncology|February 17, 2026
CDK4/6 inhibition provides additional efficacy in HER2<sup>+</sup>, HR<sup>+</sup> breast cancerDavid Killock
Nature Reviews. Clinical Oncology|May 13, 2015
Lung cancer: a new generation of EGFR inhibitionDavid Killock
Nature Reviews. Clinical Oncology|May 6, 2015
Head and neck cancer: second-line afatinib shows promiseDavid Killock
Nature Reviews. Clinical Oncology|June 21, 2020
ICI rechallenge in mRCCDavid Killock
Nature Reviews. Clinical Oncology|May 27, 2015
Gynaecological cancer: Biomarker potential of CA-125 enhancedDavid Killock
Pageof 31

Showing results (81-90 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|March 8, 2022
Maintenance capecitabine is beneficial in NPCDavid Killock
Nature Reviews. Clinical Oncology|May 9, 2019
GITR agonism - combination is keyDavid Killock
Nature Reviews. Clinical Oncology|July 28, 2023
Adjuvant nivolumab shows promise in MCCDavid Killock
Nature Reviews. Clinical Oncology|July 21, 2023
Platinum-ineligible: atezolizumab preferableDavid Killock
Nature Reviews. Clinical Oncology|June 24, 2024
Vimseltinib improves outcomes in tenosynovial giant cell tumourDavid Killock
Nature Reviews. Clinical Oncology|February 17, 2026
CDK4/6 inhibition provides additional efficacy in HER2<sup>+</sup>, HR<sup>+</sup> breast cancerDavid Killock
Nature Reviews. Clinical Oncology|May 13, 2015
Lung cancer: a new generation of EGFR inhibitionDavid Killock
Nature Reviews. Clinical Oncology|May 6, 2015
Head and neck cancer: second-line afatinib shows promiseDavid Killock
Nature Reviews. Clinical Oncology|June 21, 2020
ICI rechallenge in mRCCDavid Killock
Nature Reviews. Clinical Oncology|May 27, 2015
Gynaecological cancer: Biomarker potential of CA-125 enhancedDavid Killock
Pageof 31